8-K - Lisata Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Lisata Therapeutics and Kuva Labs agreed to extend the deadline to commence a tender offer under their merger agreement from April 3, 2026, to April 13, 2026.

Key Takeaways

1The parties executed a waiver to extend the tender offer commencement date by ten days, moving the deadline from April 3, 2026, to April 13, 2026.

2The extension modifies the original Agreement and Plan of Merger dated March 6, 2026, specifically adjusting the timeline in Section 1.1(a).

3The waiver extends the commencement period to 26 Business Days after the Merger Agreement date, up from the original 20 Business Days.

4All other terms and conditions of the Merger Agreement remain unchanged and in full force.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

| Other Events | |---|---| On April 2, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), togeth

Other Event

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits. Number: 99.1 | Description of Exhibit: Waiver to Agreement and Plan of Merger, dated April 2, 202

Exhibits Only

Source Document

Transaction Details

Acquisition / Disposition

Target: Lisata Therapeutics, Inc.
Consideration: Not disclosed
Structure: Tender Offer followed by Merger

•Merger Agreement dated March 6, 2026
•Tender offer commencement deadline extended from April 3, 2026 to April 13, 2026
•Offer to be commenced within 26 Business Days after the date of the Merger Agreement

Exhibits (2)

8-K

99.1

EXHIBIT 99.1